Roy S. Herbst
Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial.
Overview
Roy Herbst (Yale Cancer Center) led KEYNOTE-010, the trial that established pembrolizumab for previously treated PD-L1-positive NSCLC, and was co-principal investigator of ADAURA, which showed adjuvant osimertinib dramatically cuts recurrence and improves survival in resected EGFR-mutant lung cancer. He co-led the Lung-MAP master protocol and the early atezolizumab biomarker work. His current focus is adjuvant and neoadjuvant targeted therapy.
Pages like this
not linked directly; found by shared links- PersonMartin Reck
Shares Atezolizumab, Pembrolizumab, PD-1, Non-small-cell lung cancer and the tags lung, immunotherapy.
- PersonYi-Long Wu
Shares ADAURA, ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Osimertinib, EGFR.
- PersonThierry André
Shares Pembrolizumab, PD-1 and the tags immunotherapy, adjuvant.
- PersonArjun V. Balar
Shares Atezolizumab, Pembrolizumab, PD-1 and the tag immunotherapy.
- PersonTina Cascone
Shares PD-1, Non-small-cell lung cancer and the tags lung, immunotherapy.
- TrialLAURA
Shares Osimertinib, EGFR, Non-small-cell lung cancer.
- PersonMyung-Ju Ahn
Shares Osimertinib, EGFR, Non-small-cell lung cancer and the tag lung.
- PersonDean F. Bajorin
Shares PD-1 and the tags immunotherapy, adjuvant.